Fig. 2. Vactosertib promotes the regression of fibrotic plaques. (A) Representative figures of Masson trichrome staining in age-matched controls and Peyronie's disease (PD) rats that received Vactosertib (10 mg/kg) or vehicle. Dotted line represents the area of fibrotic plaques. Scale bar indicates 100 µm. (B) Quantification of the plaque areas. An image analyzer was used to quantitate the plaque areas. The area of the vehicle-treated PD group was arbitrarily set to 100%. Each bar depicts the mean value (±standard errors) of n=6 animals per group. ap<0.01, compared with the control group; bp<0.01, compared with the PD+Vactosertib group.
